ARPP21 mutations reveal the role of RNA granule dysfunction in ALS and FTD

Add to your list(s) Download to your calendar using vCal

• Christopher E Shaw, King's College London
• Wednesday 16 January 2019, 10:00-11:00
• Department of Chemistry, Cambridge, Unilever lecture theatre.

If you have a question about this talk, please contact Gabriella Heller.

Amyotrophic Lateral Sclerosis (ALS) and fronto-temporal lobar dementia (FTD) are associated with the pathological aggregation of proteins involved in RNA processing, most commonly TDP -43 and rarely FUS . Many other mutant genes can contribute to TDP -43 aggregation and some of these are also directly involved in RNA processing (ATXN2, hnRNPA1, hnRNPA2B1 and MATR3 ).

I will present unpublished evidence that novel variants in ARPP21 are associated with ALS and FTD . ARPP21 encodes a neuronally expressed, cytoplasmic RNA -binding protein involved in mRNA transport. Mutations increase the propensity of ARPP21 and TDP -43 to aggregate and become insoluble in an RNA -binding dependent manner. Mutations disrupt RNA granule transport in primary neurons and enhance neurotoxicity in the Drosophila eye. This discovery reveals new insights into the role of RNA granule dysfunction in ALS and FTD and challenges several assumptions about the pathophysiology of these neurodegenerative disorders.

This talk is part of the Biophysical Seminars series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biophysical Seminar Series 2016/17
• Biophysical Seminars
• Department of Chemistry
• Department of Chemistry, Cambridge, Unilever lecture theatre
• Featured lists
• School of Physical Sciences

Note that ex-directory lists are not shown.